Tokio Marine Asset Management Co. Ltd. Purchases 1,867 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Tokio Marine Asset Management Co. Ltd. lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,221 shares of the biopharmaceutical company’s stock after acquiring an additional 1,867 shares during the quarter. Tokio Marine Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $4,395,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in GILD. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth about $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the 1st quarter worth about $29,000. Core Alternative Capital lifted its holdings in Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 241 shares during the last quarter. IMA Advisory Services Inc. purchased a new stake in Gilead Sciences during the first quarter valued at about $39,000. Finally, Clearstead Trust LLC lifted its holdings in Gilead Sciences by 287.6% during the first quarter. Clearstead Trust LLC now owns 376 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 279 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.1%

Shares of Gilead Sciences stock opened at $120.14 on Thursday. The company’s 50 day moving average price is $111.59 and its 200-day moving average price is $108.00. Gilead Sciences, Inc. has a 52-week low of $72.89 and a 52-week high of $121.83. The stock has a market capitalization of $149.07 billion, a price-to-earnings ratio of 23.93, a P/E/G ratio of 0.75 and a beta of 0.33. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter last year, the firm posted $2.01 earnings per share. The firm’s revenue was up 1.4% on a year-over-year basis. Equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Analysts Set New Price Targets

Several research firms have commented on GILD. Cantor Fitzgerald began coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Truist Financial raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the company from $108.00 to $127.00 in a report on Friday, August 8th. Royal Bank Of Canada upped their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a report on Friday, August 8th. Needham & Company LLC raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price objective on the stock in a report on Friday, July 25th. Finally, Morgan Stanley upped their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a report on Friday, April 25th. Seven research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $114.82.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $333,090.00. Following the completion of the sale, the insider owned 117,168 shares of the company’s stock, valued at $13,009,163.04. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the sale, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. The trade was a 1.62% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 79,500 shares of company stock worth $8,734,625. Insiders own 0.27% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.